Key Points
- Insider selling continued: Mark Hopman sold 821 Beta Bionics shares at $20 each for $16,420, reducing his position by 1.48% to 54,513 shares. He has also made several larger sales since September.
- Shares declined 16.5%: BBNX opened at $17.85, despite Beta Bionics reporting a quarterly loss of $0.52 per share that narrowly beat estimates and revenue of $35.51 million.
- Legal and regulatory concerns are weighing on sentiment: Multiple law firms announced a potential securities class action alleging inadequate disclosures related to FDA compliance and more than 18,000 iLet complaints, though the allegations have not been proven.
Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) insider Mark Hopman sold 821 shares of the stock in a transaction on Monday, October 26th. The shares were sold at an average price of $20.00, for a total value of $16,420.00. Following the completion of the transaction, the insider directly owned 54,513 shares in the company, valued at approximately $1,090,260. This represents a 1.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Mark Hopman also recently made the following trade(s):
- On Wednesday, October 14th, Mark Hopman sold 775 shares of Beta Bionics stock. The shares were sold at an average price of $17.35, for a total value of $13,446.25.
- On Thursday, October 1st, Mark Hopman sold 370 shares of Beta Bionics stock. The stock was sold at an average price of $18.96, for a total value of $7,015.20.
- On Wednesday, September 16th, Mark Hopman sold 30,779 shares of Beta Bionics stock. The stock was sold at an average price of $20.13, for a total value of $619,581.27.
- On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The stock was sold at an average price of $18.46, for a total value of $680,620.20.
- On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total value of $101,798.97.
Beta Bionics Trading Down 16.5%
Shares of Beta Bionics stock opened at $17.85 on Thursday. The firm has a market capitalization of $803.07 million, a PE ratio of -10.82 and a beta of 3.39. The business's 50-day moving average price is $19.21 and its 200-day moving average price is $14.90. Beta Bionics, Inc. has a 12 month low of $8.80 and a 12 month high of $32.71.
Beta Bionics (NASDAQ:BBNX - Get Free Report) last announced its quarterly earnings data on Tuesday, October 27th. The company reported ($0.52) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.01. The company had revenue of $35.51 million for the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. As a group, analysts predict that Beta Bionics, Inc. will post -2.02 earnings per share for the current fiscal year.
Key Stories Impacting Beta Bionics
Here are the key news stories impacting Beta Bionics this week:
- Positive Sentiment: Third-quarter results modestly exceeded expectations. Beta Bionics reported a loss of $0.52 per share versus the consensus loss estimate of $0.53. Revenue reached $35.51 million, above the approximately $34.7 million analyst estimate. The company also updated its full-year 2026 guidance, although the details were not provided in the available reports. Beta Bionics Announces Third Quarter 2026 Financial Results
- Neutral Sentiment: Insider sale was limited in size. Director Mark Hopman sold 821 shares at an average price of $20, reducing his position by about 1.48%. While insider selling can weigh on sentiment, the transaction represented a relatively small portion of his holdings. SEC Insider Filing
- Negative Sentiment: Multiple law firms publicized a pending securities class action. The lawsuit covers investors who purchased BBNX securities from July 30, 2025, through February 24, 2026, with a November 3, 2026 deadline to seek lead-plaintiff status. The repeated notices increase legal and reputational concerns, although the allegations have not been proven.
- Negative Sentiment: The allegations center on iLet safety and regulatory disclosures. Legal notices allege Beta Bionics failed to disclose material information, including a June 2025 FDA Form 483 and more than 18,000 unreported iLet-related complaints. The firms contend that subsequent disclosures concerning FDA compliance and device safety were followed by a sharp stock decline. Any litigation costs, regulatory action, or additional product issues could further pressure the shares. Beta Bionics Securities Fraud Class Action Notice
Wall Street Analyst Weigh In
A number of brokerages have commented on BBNX. TD Cowen lifted their price target on shares of Beta Bionics from $18.00 to $21.00 and gave the stock a "hold" rating in a research note on Wednesday. Bank of America boosted their price objective on shares of Beta Bionics from $18.00 to $20.00 and gave the stock a "neutral" rating in a report on Tuesday, September 15th. Truist Financial upped their price objective on shares of Beta Bionics from $23.00 to $28.00 and gave the company a "buy" rating in a research note on Thursday, September 24th. The Goldman Sachs Group increased their target price on shares of Beta Bionics from $17.00 to $19.00 and gave the company a "buy" rating in a report on Wednesday, July 15th. Finally, UBS Group reaffirmed a "buy" rating and set a $25.00 target price on shares of Beta Bionics in a report on Tuesday, September 15th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $23.69.
Get Our Latest Analysis on BBNX
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in Beta Bionics during the 2nd quarter valued at about $52,340,000. Eversept Partners LP grew its position in Beta Bionics by 108.6% during the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company's stock worth $14,177,000 after acquiring an additional 736,576 shares during the last quarter. Bank of America Corp DE bought a new position in Beta Bionics during the 2nd quarter worth approximately $8,566,000. Perceptive Advisors LLC grew its position in Beta Bionics by 39.8% during the 1st quarter. Perceptive Advisors LLC now owns 842,944 shares of the company's stock worth $8,446,000 after acquiring an additional 240,000 shares during the last quarter. Finally, Bruce & Co. Inc. purchased a new position in Beta Bionics in the 1st quarter worth approximately $5,518,000.
About Beta Bionics
(
Get Free Report)
Beta Bionics, Inc (NASDAQ: BBNX) is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.
The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual's glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
